Beneficial Ownership Report · SCHEDULE 13G
BioStem Technologies, Inc.
BSEMNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- BioStem Technologies, Inc.
- Company CIK
- 0001658678
- Street
- 2836 Center Port Circle
- City
- Pompano Beach
- State / country code
- FL
- Postal code
- 33064
Statement details
- Security class
- Common Stock, $0.001 par value (the "Common Stock")
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(d)
Reporting person 1
- Name
- Jason Matuszewski
- Citizenship / organization
- X1
- Reporting person type
- IN
- Aggregate amount owned
- 3,665,899.00
- Percent of class
- 17.4
- Sole voting power
- 3,665,899.00
- Shared voting power
- 0.00
- Sole dispositive power
- 3,665,899.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
- Comments
- (1) Based on 18,672,125 shares of Common Stock outstanding as of October 1, 2026, as reported in the Issuer's Registration Statement on Form S-1 filed on October 2, 2026, plus 2,362,348 shares issuable to the Reporting Person upon exercise or conversion of derivative securities exercisable within 60 days of September 30, 2026, computed in accordance with Rule 13d-3(d)(1)(i).
Item 1
Issuer
BioStem Technologies, Inc.
Principal executive office address
2836 Center Port Circle, Pompano Beach, Florida 33064
Item 2
Citizenship
United States.
Filing person
Jason Matuszewski (the "Reporting Person").
Principal business or residence address
c/o BioStem Technologies, Inc., 2836 Center Port Circle, Pompano Beach, Florida 33064.
Item 3
Not applicable indication
Y
Item 4
Percent of class
17.4%. See footnote (1) to the cover page.
Amount beneficially owned
3,665,899 shares of Common Stock, consisting of: (i) 1,303,551 shares of Common Stock held directly; (ii) 2,250,000 shares of Common Stock issuable upon exercise of fully vested options with an exercise price of $2.00 per share expiring October 24, 2032; (iii) 98,907 shares of Common Stock issuable upon exercise of the vested portion of options to purchase 198,807 shares at $10.05 per share expiring March 17, 2035; (iv) 13,341 shares of Common Stock issuable upon exercise of the portion of options to purchase 40,427 shares at $10.05 per share expiring October 13, 2035 that vests on October 13, 2026; and (v) 100 shares of Common Stock issuable upon conversion of 100 Series A-1 Convertible Preferred Shares. The amount excludes restricted stock units covering an aggregate of 497,411 shares not scheduled to vest on or before November 29, 2026. The amount also excludes options to purchase 440,529 shares at $5.50 per share not scheduled to vest on or before November 29, 2026.
Sole voting power
3,665,899
Shared voting power
0
Sole dispositive power
3,665,899
Shared dispositive power
0
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
Y
Signature 1
- Reporting person
- Jason Matuszewski
- Signed
- /s/ Jason Matuszewski
- Title
- Jason Matuszewski
- Date
- 11/10/2026
Company context
BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.